Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Hilmi

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Nature Biotechnology|September 25, 2023
Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responsesMenglin Wang, Benoit Rousseau, Kunyu Qiu, et al.
Biorxiv : the Preprint Server for Biology|March 27, 2026
POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancerWungki Park, Shigeaki Umeda, Marc Hilmi, et al.
Medrxiv : the Preprint Server for Health Sciences|May 18, 2026
Anatomical dynamics define cancer cachexia subtypes and identify systemic inflammation as a marker of lethal wastingSonia Boscenco, Venise Jan Castillon, Jamie Wang, et al.
Research Square|September 15, 2025
Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II TrialWungki Park, Catherine O'Connor, Joanne Chou, et al.
Nature Medicine|March 26, 2026
Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trialWungki Park, Catherine A O'Connor, Joanne F Chou, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Nature Biotechnology|September 25, 2023
Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responsesMenglin Wang, Benoit Rousseau, Kunyu Qiu, et al.
Biorxiv : the Preprint Server for Biology|March 27, 2026
POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancerWungki Park, Shigeaki Umeda, Marc Hilmi, et al.
Medrxiv : the Preprint Server for Health Sciences|May 18, 2026
Anatomical dynamics define cancer cachexia subtypes and identify systemic inflammation as a marker of lethal wastingSonia Boscenco, Venise Jan Castillon, Jamie Wang, et al.
Research Square|September 15, 2025
Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II TrialWungki Park, Catherine O'Connor, Joanne Chou, et al.
Nature Medicine|March 26, 2026
Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trialWungki Park, Catherine A O'Connor, Joanne F Chou, et al.
Pageof 5